Actively Recruiting
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Led by Boryung Pharmaceutical Co., Ltd · Updated on 2025-09-15
9000
Participants Needed
1
Research Sites
116 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
CONDITIONS
Official Title
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with type 2 diabetes mellitus and hypertension
- Planned to receive Trudapa Tab. or Trudapa M SR Tab.
- Voluntarily agreed to participate by signing a written consent
- Able to understand and cooperate with the study and complete it
You will not qualify if you...
- Have secondary hypertension such as coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome, or polycystic kidney disease
- Used dapagliflozin within 4 weeks before starting the study
- Expected to require insulin treatment during the study
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Gachon University Gil Medical Center
Incheon, Namdong-gu, South Korea, 21565
Actively Recruiting
Research Team
S
Shinyoung Oh
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here